We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

MedXY Editorial Team•Feb 9, 2026•Diabetes & Endocrinology
albuminuriachronic kidney diseaseDiabetes MellitusSGLT2 inhibitors

Highlight

Broad Efficacy Across Subgroups

SGLT2 inhibitors (SGLT2i) demonstrated a consistent reduction in kidney disease progression, acute kidney injury (AKI), and all-cause hospitalization regardless of whether a patient has type 2 diabetes or the level of baseline albuminuria.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for CliniciansKDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.Sep 18, 2026SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective StudySGLT2 inhibitors administered after endovascular thrombectomy in diabetic stroke patients significantly improve 3-month functional outcomes, suggesting a promising adjunctive therapy for poststroke diabetes management.Sep 18, 2026Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort StudyA large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management straSep 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Finerenone in Hypertensive Non-Diabetic Chronic Kidney Disease: Evidence from the FIND-CKD Subgroup Analysis
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
Sep 3, 2026
Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical ChallengesThis article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.Aug 12, 2026
End-Organ Damage in Primary Hyperparathyroidism: Prevalence, Progression, and Treatment Gaps in a National CohortA nationwide cohort study reveals that two-thirds of patients with primary hyperparathyroidism exhibit end-organ damage at diagnosis or during follow-up, yet few receive parathyroidectomy, underscoring missed opportunities to reduce morbidiAug 4, 2026